Optimization of current and future therapy for autoimmune diseases

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Stephen Sawcer, Maria Ban, Anu Kemppinen et al. · Nature · 2011 · 2.7K citations · Full text

Life Sciences, Immunology, Neurology +17

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine · 2010 · 2.6K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Vanda A. Lennon, Thomas J. Kryzer, Sean J. Pittock et al. · The Journal of Experimental Medicine · 2005 · 2.3K citations · Full text

Life Sciences, Neurology, Neuroscience +17

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet · 2011 · 2K citations

Medicine, Immunology, Pharmacology +11